Intuit Currently Up Seven Consecutive Days, On Track for Longest Winning Streak Since October 2021 — Data Talk
Intuit Inc. ( INTU ) is currently at $554.90, up $3.94 or 0.72%
--Would be highest close since Feb. 10, 2022, when it closed at $557.58
--Currently up eight of the past nine days
--Currently up seven consecutive days; up 6.94% over this period
--Longest winning streak since Oct. 29, 2021, when it rose for seven straight trading days
--Best seven day stretch since the seven days ending July 19, 2023, when it rose 7.8%
--Up 2.42% month-to-date
--Up 42.57% year-to-date
--Down 20.12% from its all-time closing high of $694.66 on Nov. 29, 2021
--Up 26.39% from 52 weeks ago (Sept. 8, 2022), when it closed at $439.04
--Would be a new 52-week closing high
--Up 53.63% from its 52-week closing low of $361.19 on Nov. 4, 2022
--Traded as high as $557.03; highest intraday level since Feb. 11, 2022, when it hit $561.70
--Up 1.1% at today's intraday high
All data as of 11:10:38 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 07, 2023 11:29 ET (15:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track